Research Topics
Species | Mary SanoSummaryAffiliation: Mount Sinai School of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Schizophrenia in a patient with spinocerebellar ataxia 2: coincidence of two disorders or a neurodegenerative disease presenting with psychosis?Matthew Rottnek
Department of Neurology, James J Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA
Am J Psychiatry 165:964-7. 2008
Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivoJohn W Steele
Departments of Neurology, Psychiatry and Alzheimer s Disease Research Center, Mount Sinai School of Medicine, New York, NY, 10029, USA
Mol Neurodegener 4:51. 2009..In the current study, we assessed the effect of acute dosing of latrepirdine on levels of extracellular Abeta using in vitro and in vivo experimental systems...- Current concepts in the prevention of Alzheimer's diseaseMary Sano
Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
CNS Spectr 8:846-53. 2003..Information can also be gathered when dementia evaluation is added to ongoing studies. As results from these studies becoming available, we will be able to refine our approach to managing this disease... - Noncholinergic treatment options for Alzheimer's diseaseMary Sano
Bronx Veterans Medical Research Development, Bronx, NY 10468 3904, USA
J Clin Psychiatry 64:23-8. 2003..The cost of these studies is high, but the potential benefit of delay or prevention of disease is the valuable goal... - The effects of galantamine treatment on caregiver time in Alzheimer's diseaseMary Sano
Mount Sinai School of Medicine Veterans Affairs Hospital, Bronx, NY 10468, USA
Int J Geriatr Psychiatry 18:942-50. 2003..The aim of the study was to determine whether the clinical benefits of galantamine for patients with Alzheimer's disease lead to benefits for caregivers... - A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer diseaseM Sano
Mount Sinai School of Medicine, Bronx, NY 10468, USA
Neurology 77:556-63. 2011.... - A guide to diagnosis of Alzheimer's diseaseMary Sano
Bronx Veterans Administration Hospital, 130 W Kingsbridge Road, Bronx, NY 10468, USA
CNS Spectr 9:16-9. 2004..The issues of cognitive screening in old age and age-associated memory impairment will be discussed. Similarly, the pitfalls and advantages of routine cognitive screening in daily practice will be addressed... - Economic effect of cholinesterase inhibitor therapy: implications for managed careMary Sano
Alzheimer Disease Research Center, Mount Sinai School of Medicine, Bronx Veterans Administration Medical Center, Bronx, New York 10468, USA
Manag Care Interface 17:44-9. 2004..The cost savings range from 73 dollars over two years to 3891 dollars over one year, depending on the type of study, drug evaluated, and economic model employed in the evaluation... - Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trialsMary Sano
Mount Sinai School of Medicine, Bronx, NY, USA
Alzheimer Dis Assoc Disord 20:232-41. 2006.... 
ICAD 2010: Detection may hold the key to treatment. International Conference on Alzheimer Disease (ICAD) 2010 Honolulu, HI, USA, 10–15 July 2010Mary Sano
James J Peters Veterans Administrations Medical Center, Department of Psychiatry, Mount Sinai School of Medicine, 130 W Kingsbridge Rd, Code 150 Rm 1F01, Bronx, NY 10468, USA
Expert Rev Neurother 10:1659-61. 2010..Key themes of this year's conference included validation of biomarkers, drug development, the value of screening for cognitive loss and dementia and the proposal of a new criteria for Alzheimer's disease...- Neuropsychological testing in the diagnosis of dementiaMary Sano
Alzheimer Disease Research Center of Mount Sinai School of Medicine, New York, NY, USA
J Geriatr Psychiatry Neurol 19:155-9. 2006.... - Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer diseaseMary Sano
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
Alzheimer Dis Assoc Disord 25:122-7. 2011..To determine if the addition of delayed recall (DR) assessment adds sensitivity to the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) in clinical trials in mild cognitive impairment (MCI) and Alzheimer Disease (AD)... - ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderlyMary Sano
Mount Sinai School of Medicine, James J Peters VAMC, Bronx, NY 10468, USA
Alzheimer Dis Assoc Disord 20:S191-202. 2006..In addition, the loss that relates to the subjects' own time as they transition through cognitive impairment is not well documented... - Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years oldMary Sano
Mount Sinai School of Medicine, New York, USA
Alzheimer Dis Assoc Disord 24:256-63. 2010..This report describes a pilot study to evaluate feasibility of new home-based assessment technologies applicable to clinical trials for prevention of cognitive loss and Alzheimer disease... - Undertreatment of patients with Alzheimer's disease in an elderly United States populationMary Sano
Mount Sinai School of Medicine, Bronx Veterans Medical Research Center, 130 W Kingsbridge Rd, Bronx, NY 10468, USA
Alzheimers Dement 1:136-44. 2005.... - A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristicsMary Sano
Mount Sinai School of Medicine, Department of Psychiatry, New York, NY, USA
Clin Trials 5:523-33. 2008..Observational studies and small clinical trials suggested that hormone replacement therapy (HRT) decreases risk of cognitive loss and Alzheimer's disease (AD) in postmenopausal women and may have value in primary prevention... - Preventing Alzheimer's disease : separating fact from fictionMary Sano
The Alzheimer Disease Research Center of Mount Sinai School of Medicine, New York, New York, USA
CNS Drugs 22:887-902. 2008..We review the evidence from completed trials, support for ongoing studies and propose directions for future research... - Patient dependence and longitudinal changes in costs of care in Alzheimer's diseaseCarolyn W Zhu
Geriatric Research, Education, and Clinical Center GRECC, James J Peters VA Medical Center, Bronx, NY, NY 10468, USA
Dement Geriatr Cogn Disord 26:416-23. 2008..To examine the incremental effect of patients' dependence on others, on cost of medical and nonmedical care, and on informal caregiving hours over time... - ADCS Prevention Instrument Project: overview and initial resultsSteven H Ferris
Alzheimer s Disease Center, New York University School of Medicine, New York, NY 10016, USA
Alzheimer Dis Assoc Disord 20:S109-23. 2006..Initial results for the experimental instruments and for the book club are reported in separate accompanying articles... - C-reactive protein and familial risk for dementia: a phenotype for successful cognitive agingJeremy M Silverman
Department of Psychiatry, Mount Sinai School of Medicine, New York, USA
Neurology 79:1116-23. 2012.... - Cardiovascular risk and memory in non-demented elderly womenSophia Wang
Alzheimer Disease Research Center, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
Neurobiol Aging 31:1250-3. 2010..To determine whether cardiovascular (CV) risk is associated with subtle memory deficits in non-demented, healthy older women with a family history of Alzheimer disease (AD)... - Cognition in non-demented diabetic older adultsSirisha Nandipati
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
Curr Aging Sci 5:131-5. 2012..A specific role of diabetes as a risk for cognitive impairment will require longitudinal study... - The effects of patient function and dependence on costs of care in Alzheimer's diseaseCarolyn W Zhu
Geriatric Research, Education, and Clinical Center, Program of Research on Serious Physical and Mental Illness, James J Peters Veterans Affairs Medical Center, Bronx, New York 10468, USA
J Am Geriatr Soc 56:1497-503. 2008..To estimate incremental effects of patients' dependence and function on costs of care during the early stages of Alzheimer's disease (AD) and to compare strengths of their relationships with different cost components... - Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depressionMichael A Rapp
Department of Psychiatry, Mount Sinai School of Medicine, New York, USA
Am J Geriatr Psychiatry 16:168-74. 2008..The authors tested the hypothesis that neuritic plaques and neurofibrillary tangles are more pronounced in the brains of patients with AD with comorbid depression as compared with patients with AD without depression... - Increased presence of cognitive impairment in hemodialysis patients in the absence of neurological eventsJames B Post
Nephrology Division, James J Peters Veterans Affairs Medical Center, Bronx, NY, USA
Am J Nephrol 35:120-6. 2012..The aim was to compare cognitive function in HD patients with no history of stroke or dementia and well-matched controls. Studies are required to determine the impact of HD and chronic kidney disease-specific risks on CI... - Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depressionMichael A Rapp
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
Arch Gen Psychiatry 63:161-7. 2006..Although there is increasing evidence that major depression may interact with neuropathological processes in AD, there have been no studies of neuropathological changes in AD as a function of history of major depression... - Home health and informal care utilization and costs over time in Alzheimer's diseaseCarolyn W Zhu
Geriatric Research, Education, and Clinical Center GRECC, James J Peters VA Medical Center, Bronx, NY 10468, USA
Home Health Care Serv Q 27:1-20. 2008.... - Cognitive performance in community-dwelling English- and Spanish-speaking seniorsAlex D Federman
Division of General Internal Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
Age Ageing 38:669-75. 2009..to examine the association of language (English vs Spanish), and commonly used measures of memory and word fluency among older adults... - Heritability of cognitive functions in families of successful cognitive aging probands from the Central Valley of Costa RicaTiffany A Greenwood
Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
J Alzheimers Dis 27:897-907. 2011.... - Comparison of costs of care between patients with Alzheimer's disease and dementia with Lewy bodiesCarolyn W Zhu
Geriatric Research, Education, and Clinical Center and Program of Research on Serious Physical and Mental Illness, Targeted Research Enhancement Program, James J Peters VA Medical Center, Bronx, NY, USA
Alzheimers Dement 4:280-4. 2008..This cross-sectional analysis of baseline data from the Predictors II Study took place in three university-based AD centers in the U.S... - Utilization of antihypertensives, antidepressants, antipsychotics, and hormones in Alzheimer diseaseCarolyn W Zhu
Geriatric Research, Education, and Clinical Center GRECC and Health Services Research and Development HSR and D Center for Study of Health Care across Systems and Sites of Care, James J Peters VA Medical Center, Bronx, New York, NY 10468, USA
Alzheimer Dis Assoc Disord 25:144-8. 2011..Findings suggest accurate modeling of the Alzheimer disease treatment paradigm for certain subgroups of patients should include antihypertensives and antipsychotics in addition to cholinesterase inhibitors and memantine... - Impact of APOE epsilon4 on the cognitive performance of a sample of non-demented Puerto Rican nonagenariansJOSE R CARRION-BARALT
Mount Sinai School of Medicine, Department of Psychiatry, New York, NY, USA
J Alzheimers Dis 18:533-40. 2009..In conclusion, the results of this study suggest that, among these Puerto Rican non-demented nonagenarians, being an APOE epsilon4 allele carrier is associated with better cognition... - Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family StudyRobert A Sweet
Department of Psychiatry, University of Pittsburgh, Biomedical Science Tower, Rm W 1645, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
Brain 133:1155-62. 2010..Future studies should examine the linkage and association of psychosis with genetic variation within these families... - Evaluating cognition in an elderly cohort via telephone assessmentEffie M Mitsis
Alzheimer s Disease Research Center, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
Int J Geriatr Psychiatry 25:531-9. 2010..We examined the feasibility, and its comparability to in-person assessment, of a telephone administered battery of established neuropsychological measures of cognitive functioning in healthy, elderly women... - Synaptic protein deficits are associated with dementia irrespective of extreme old ageMichal Schnaider Beeri
Mount Sinai School of Medicine, Department of Psychiatry, New York, NY 10029, USA
Neurobiol Aging 33:1125.e1-8. 2012.... - Relationship of neuropsychological performance to functional status in nursing home residents and community-dwelling older adultsMichael A Rapp
Dept of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, Box 1240, New York, NY 10029 6574, USA
Am J Geriatr Psychiatry 13:450-9. 2005..The authors examined the association between neuropsychological tests of executive functioning and episodic memory and functional disability in nursing home residents versus community-dwelling older adults... - Cognitive profile of chronic kidney disease and hemodialysis patients without dementiaJames B Post
Nephrology Division, James J Peters Veterans Affairs Medical Center, Bronx, N Y 10468, USA
Nephron Clin Pract 116:c247-55. 2010..We aimed to assess cognitive function in CKD and HD patients with no history of stroke or dementia, in order to identify and characterize early cognitive deficits... - The neuropsychological performance of nondemented Puerto Rican nonagenariansJOSE R CARRION-BARALT
Department of Psychiatry, Mount Sinai School of Medicine, New York, N Y, USA
Dement Geriatr Cogn Disord 27:353-60. 2009..This study sought to evaluate the neuropsychological performance of nondemented nonagenarians residing in Puerto Rico and to compare their results with those of a similar English-speaking sample from New York... - Profiles of Alzheimer's disease-related pathology in an aging urban population sample in IndiaDushyant P Purohit
Department of Pathology, Mount Sinai School of Medicine, New York, NY, USA
J Alzheimers Dis 24:187-96. 2011.... - Cognitive performance in hypotensive persons with spinal cord injuryAdejoke B Jegede
VA Rehabilitation Research and Development Service, Center of Excellence for the Medical Consequences of Spinal Cord Injury, James J Peters VA Medical Center, Rm 1E 02 130 West Kingsbridge Rd, Bronx, NY, 10468, USA
Clin Auton Res 20:3-9. 2010..Several investigations in the non-SCI population have noted a relationship between chronic hypotension and deficits in memory, attention and processing speed and delayed reaction times... - Health literacy and cognitive performance in older adultsAlex D Federman
Division of General Internal Medicine Development, Mount Sinai School of Medicine, New York, New York 10029, USA
J Am Geriatr Soc 57:1475-80. 2009..To study the relationship between health literacy and memory and verbal fluency in older adults... - Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the communityCarolyn W Zhu
Geriatric Research, Education, and Clinical Center and Program of Research on Serious Physical and Mental Illness, James J Peters Department of Veterans Affairs Medical Center, Bronx, New York 10468, USA
J Am Geriatr Soc 54:1596-602. 2006..Each additional point on the BDRS increased informal caregiving costs 5.4%. Average annual informal cost was estimated at $25,381 per patient, increasing from $20,589 at baseline to $43,030 in Year 4... - Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individualsMichal Schnaider Beeri
Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY 10029, United States
Mech Ageing Dev 132:583-7. 2011..Serum levels are increased in diabetes and aging. We examined the relationship between serum methylglyoxal derivatives (sMG), and cognitive decline, in 267 non-demented elderly... - Cross-domain variability of cognitive performance in very old nursing home residents and community dwellers: relationship to functional statusMichael A Rapp
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
Gerontology 51:206-12. 2005..Recent evidence suggests that cross-domain variability in cognition may be related to subsequent cognitive decline beyond mean performance levels in cognitive tasks... - Women's cognitive and affective health and neuropsychiatryAmy Aloysi
The Alzheimer Disease Research Center, Mount Sinai School of Medicine, New York, NY, USA
Mt Sinai J Med 73:967-75. 2006.... - Health-related resource use and costs in elderly adults with and without mild cognitive impairmentCarolyn W Zhu
Department of Geriatrics and Palliative Medicine, Alzheimer Disease Research Center, Bronx, NY 10468, USA
J Am Geriatr Soc 61:396-402. 2013..To assess differences in resource use and cost between older adults with and without mild cognitive impairment (MCI) over time... - Neuropsychological differences between late-onset and recurrent geriatric major depressionMichael A Rapp
Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, Box 1230, New York, NY 10029, USA
Am J Psychiatry 162:691-8. 2005..The purpose of this study was to explore differences in neuropsychological function, symptoms, and cardiovascular comorbidity between patients with late-onset and recurrent geriatric major depression... - Prevention of Alzheimer's disease: where we standMary Sano
Department of Neurology, College of Physicians and Surgeons of Columbia University, 630 W 168th Street, Box 16, New York, NY 10032, USA
Curr Neurol Neurosci Rep 2:392-9. 2002..This review begins by examining the progress that has been made in this disease. Current efforts to develop prevention strategies are described and possible agents for future evaluation are discussed... - Economic considerations in the management of Alzheimer's diseaseCarolyn W Zhu
Geriatric Research, Education, and Clinical Center GRECC and Program of Research on Serious Physical and Mental Illness, Targeted Research Enhancement Program TREP, Bronx VA Medical Center, Bronx, NY 10468 USA
Clin Interv Aging 1:143-54. 2006..Continued home care for patients under pharmacological treatment may reduce caregiver burden, healthcare costs, and ultimately improve patients' and caregivers' QoL... - Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer diseaseGuiqing Cai
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
Neurobiol Aging 33:416-417.e3. 2012.... - Use of Medicare and Department of Veterans Affairs health care by veterans with dementia: a longitudinal analysisCarolyn W Zhu
Research Enhancement Award Program and Geriatric Research, Health Services Research and Development Service, James J Peters Veterans Affairs Medical Center, Bronx, New York 10468, USA
J Am Geriatr Soc 57:1908-14. 2009..Efforts to coordinate care between VA and Medicare providers are necessary to ensure that patients receive high-quality care, especially patients with multiple comorbidities... - The impact of nutrition on cognition in the elderlyKathleen Van Dyk
Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
Neurochem Res 32:893-904. 2007..Clinical trials have explored these mechanisms through supplementation studies with minimal benefits being observed. Continuing work to hone the mechanisms and refine our knowledge of dietary benefits is described... - Functional neural correlates of attentional deficits in amnestic mild cognitive impairmentNicholas T Van Dam
Department of Psychology, Queens College, City University of New York, Flushing, New York, United States of America
PLoS ONE 8:e54035. 2013..Although based on a small number of patients, our findings suggest that deficits of attention, especially the executive control of attention, may significantly contribute to the behavioral and cognitive deficits of aMCI... - Protean phenotypic features of the A3243G mitochondrial DNA mutationPetra Kaufmann
Department of Neurology, The Neurological Institute, Columbia University Medical Center, New York, NY 10032, USA
Arch Neurol 66:85-91. 2009.... - An update on treatment and prevention strategies for Alzheimer's diseaseJudith Neugroschl
James J Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA
Curr Neurol Neurosci Rep 9:368-76. 2009..An update on results from pharmacologic and nonpharmacologic prevention trials is provided... - Cardiac risk factors and potential treatments in Alzheimer's diseaseChristine Bergmann
Alzheimer Disease Research Center of Mount Sinai School of Medicine, NYC, James J Peters VAMC, Bronx, NY 10468, USA
Neurol Res 28:595-604. 2006..Based on these data, we propose that early interventions at reducing these cardiovascular risk factors may have an impact on future incidence and prevalence of cognitive deficits of many etiologies including Alzheimer's disease... - No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patientsMyron F Weiner
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, USA
J Geriatr Psychiatry Neurol 15:95-8. 2002..0 for subjects in each drug arm or placebo arm versus BMTs. We concluded that teaching caregivers BMTs did not diminish long-term prescription of psychotropic drugs... - Current treatment and recent clinical research in Alzheimer's diseaseJudith Neugroschl
Mount Sinai School of Medicine, New York, NY, USA
Mt Sinai J Med 77:3-16. 2010..A brief review of the current Food and Drug Administration-approved treatments is included... - Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional lociJoseph H Lee
Gertrude H Sergievsky Center, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Arch Neurol 65:1518-26. 2008..To identify putative genetic loci related to the risk of late-onset Alzheimer disease (LOAD)... - Do dietary antioxidants prevent Alzheimer's disease?Mary Sano
Taub Institute for Alzheimer s Disease Research and the Gertrude H Sergievsky Center, Department of Neurology, College of Physicians and Surgeons of Columbia University, New York, NY, USA
Lancet Neurol 1:342. 2002 - Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trialPaul S Aisen
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
JAMA 289:2819-26. 2003.... - Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman
Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
Arch Neurol 61:59-66. 2004..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD... - A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer diseasePaul S Aisen
Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
Am J Geriatr Psychiatry 11:246-9. 2003..CONCLUSION: High-dose vitamin supplementation reduces homocysteine levels in patients with AD. The effect of supplementation on rate of cognitive decline will be assessed later in a randomized, double-blind study... - Ischemic stroke and depressionDavid W Desmond
Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
J Int Neuropsychol Soc 9:429-39. 2003..SIGH-D item analyses suggested that a reliance on nonsomatic rather than somatic symptoms would result in the most accurate diagnoses of depression after ischemic stroke... - Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationaleRichard S E Keefe
Neurocognitive Assessment Unit, Duke University Medical Center, Durham, NC 27710, USA
Schizophr Bull 29:45-55. 2003.... - Incidence of dementia after ischemic stroke: results of a longitudinal studyDavid W Desmond
Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
Stroke 33:2254-60. 2002..We conducted the present study to investigate the incidence and clinical predictors of dementia after ischemic stroke... - Mortality in patients with dementia after ischemic strokeDavid W Desmond
Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
Neurology 59:537-43. 2002..The authors investigated dementia as a predictor of long-term survival among patients with ischemic stroke... - Vitamin E and donepezil for the treatment of mild cognitive impairmentRonald C Petersen
Mayo Clinic College of Medicine, Rochester, Minn, USA
N Engl J Med 352:2379-88. 2005.... - ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trialsDavid P Salmon
Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0948, USA
Alzheimer Dis Assoc Disord 20:S139-46. 2006.... - ADCS Prevention Instrument Project: quality of life assessment (QOL)Marian B Patterson
Case Western Reserve University, Cleveland, OH, USA
Alzheimer Dis Assoc Disord 20:S179-90. 2006..We conclude that the QOL scores at baseline show sufficient range and reliability to suggest they will have utility in tracking QOL through conversion to dementia... - Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the futureWarachal E Faison
Alzheimer s Research and Clinical Programs, Neurosciences Department, Medical University of South Carolina, Charleston, South Carolina 29406, USA
Int Psychogeriatr 19:539-58. 2007..for AD to answer two questions: (1) what are the challenges to diagnose and treat AD across different ethnic groups, and (2) are there differences in response to pharmacologic interventions for AD across these different ethnic groups?.. - ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trialsDouglas Galasko
Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0624, USA
Alzheimer Dis Assoc Disord 20:S152-69. 2006..ADL change during a trial could trigger detailed evaluation or serve as an outcome measure. A brief, easily administered, and reliable ADL rating scale would assist prevention studies... - Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled studyRachelle S Doody
Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA
Lancet 372:207-15. 2008..More effective treatments are needed. We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease... - High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trialPaul S Aisen
Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
JAMA 300:1774-83. 2008..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline... - Cognitive effects of estrogens in women with cardiac disease: what we do not knowMary Sano
Am J Med 113:612-3. 2002 - Estrogen levels do not correlate with improvement in cognitionLeon J Thal
Department of Neurosciences, University of California, San Diego, School of Medicine, 9500 Gilman Dr, La Jolla, CA 92093, USA
Arch Neurol 60:209-12. 2003..To investigate whether an association exists between estradiol and estrone levels and measures of cognitive functioning in women with Alzheimer disease (AD) treated with conjugated equine estrogen (Premarin; Wyeth-Ayerst, Philadelphia, Pa)... - A roadmap for the prevention of dementia: the inaugural Leon Thal SymposiumZaven S Khachaturian
Alzheimers Dement 4:156-63. 2008 - Reliability of monitoring the clinical dementia rating in multicenter clinical trialsKimberly A Schafer
Department of Neurosciences, University of California, San Diego, CA, USA
Alzheimer Dis Assoc Disord 18:219-22. 2004..83, global CDR) agreement. CONCLUSIONS: The ADCS-CDR worksheets were reliably and consistently scored by clinical monitors, who may be considered proxy gold standards for CDR assessment... - Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesisMiguel A Pappolla
University of South Alabama, Mobile 36617, USA
Free Radic Biol Med 33:173-81. 2002..Experimental data links cholesterol and oxidative stress with some neurodegenerative aspects of AD...
Research Grants
- Alzheimer's Disease Prevention Trial with EstrogensMary Sano; Fiscal Year: 2007..This trial may represent the very last chance to determine if estrogen can have a benefit in dementia prevention and memory protection. ..
- ALZHEIMERS DISEASE PREVENTION TRIAL WITH ESTROGENSMary Sano; Fiscal Year: 2002..Participants who become demented will be informed of standard-of-care treatment and will continue to be followed at annual intervals for the length of the study. ..